Sökning: id:"swepub:oai:DiVA.org:uu-297969" > (2016) > Cost-effectiveness ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04134naa a2200433 4500 | |
001 | oai:DiVA.org:uu-297969 | |
003 | SwePub | |
008 | 160629s2016 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:134296824 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2979692 URI |
024 | 7 | a https://doi.org/10.1038/tpj.2016.412 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1342968242 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Verhoef, T. I.u UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands4 aut |
245 | 1 0 | a Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden |
264 | c 2016-06-07 | |
264 | 1 | b Springer Science and Business Media LLC,c 2016 |
338 | a print2 rdacarrier | |
520 | a We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi0 (SwePub)303012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Health Care Service and Management, Health Policy and Services and Health Economy0 (SwePub)303012 hsv//eng |
700 | 1 | a Redekop, W. K.u Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands4 aut |
700 | 1 | a Langenskiöld, Sophieu Uppsala universitet,Hälsoekonomi,Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden4 aut0 (Swepub:uu)sopla565 |
700 | 1 | a Kamali, F.u Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England4 aut |
700 | 1 | a Wadelius, Miau Uppsala universitet,Klinisk farmakogenomik och osteoporos,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)miawadel |
700 | 1 | a Burnside, G.u Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England4 aut |
700 | 1 | a Maitland-van der Zee, A-H.u Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands4 aut |
700 | 1 | a Hughes, D. A.u Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor, North Wales, Wales4 aut |
700 | 1 | a Pirmohamed, M.u Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England4 aut |
710 | 2 | a UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlandsb Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands4 org |
773 | 0 | t The Pharmacogenomics Journald : Springer Science and Business Media LLCg 16:5, s. 478-484q 16:5<478-484x 1470-269Xx 1473-1150 |
856 | 4 | u https://www.nature.com/articles/tpj201641.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-297969 |
856 | 4 8 | u https://doi.org/10.1038/tpj.2016.41 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:134296824 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy